Johnson & Johnson
(NY:
JNJ
)
165.86
+1.63 (+0.99%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,971,064
Open
164.12
Bid (Size)
165.52 (3)
Ask (Size)
165.85 (1)
Prev. Close
164.23
Today's Range
163.81 - 165.98
52wk Range
143.13 - 165.98
Shares Outstanding
2,628,679,824
Dividend Yield
2.87%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
August 30, 2024
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
August 30, 2024
JNJ appears to be in the latter stages of wave {iii} of 1.
Via
Talk Markets
Performance
YTD
+3.68%
+3.68%
1 Month
+3.17%
+3.17%
3 Month
+12.26%
+12.26%
6 Month
+3.77%
+3.77%
1 Year
+3.35%
+3.35%
More News
Read More
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
August 30, 2024
Via
Chartmill
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
August 29, 2024
Via
Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
Via
Benzinga
Exposures
Product Safety
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
August 29, 2024
Via
Benzinga
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
August 28, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy?
August 25, 2024
Via
The Motley Fool
12 Dividend Stocks to Earn Income Every Month
August 28, 2024
Via
The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
August 27, 2024
Via
The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
August 27, 2024
Via
Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
August 27, 2024
Via
Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
August 27, 2024
Via
The Motley Fool
Topics
ETFs
Johnson & Johnson Unusual Options Activity
August 19, 2024
Via
Benzinga
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
August 27, 2024
Via
The Motley Fool
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
August 26, 2024
Via
Benzinga
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
August 26, 2024
Via
Benzinga
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
August 26, 2024
From
Johnson & Johnson
Via
Business Wire
2 Unstoppable Stocks That Are Screaming Buys in August
August 26, 2024
Via
The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
August 26, 2024
Via
The Motley Fool
Topics
Government
Exposures
Political
A Big CEO Move, Big Buffett Buys, and More
August 22, 2024
Via
The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
August 22, 2024
Via
The Motley Fool
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
August 20, 2024
Via
Benzinga
Exposures
Product Safety
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt
August 20, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Johnson & Johnson to Acquire V-Wave
August 20, 2024
From
Johnson & Johnson
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.